Fundraising Fox
Paradromics
Austin, US · Founded 2015 · 124 employees on LinkedIn · 37 known investors
Find your way into Paradromics
Sign up to see every warm intro you have to Paradromics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Paradromics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Paradromics develops a brain-computer interface (BCI) system, with FDA Breakthrough Device Designations for speech decoding and digital device control, and works with academic medical institutions on translational BCI research. The company builds implantable neurotechnology aimed at clinical applications.
Also known as Paradromics · Paradromics Inc.
Founders & leadership
Paradromics was founded in 2015 by Matt Angle.
Investors · 37
How we know: a partner's Signal profile · Not right? Tell us
How we know: Alpha Edison's portfolio page · the VCSheet dataset · research · paradromics.com · Not right? Tell us
How we know: ATEL Ventures's portfolio page · Not right? Tell us
How we know: Capital Factory's portfolio page · Not right? Tell us
How we know: CloudStone Capital's portfolio page · Not right? Tell us
How we know: Deepwater Asset Management's portfolio page · Not right? Tell us
How we know: Dolby Family Ventures's portfolio page · the VCSheet dataset · research · paradromics.com · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Frontier Path VC's portfolio page · Not right? Tell us
How we know: Fusion's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
__Twitter.png)
How we know: Green Sands Equity's portfolio page · research · paradromics.com · Not right? Tell us
How we know: Harmonix Fund's portfolio page · Not right? Tell us
How we know: Hartmann Capital's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: IT-Farm Corporation's portfolio page · Not right? Tell us
How we know: the VCSheet dataset · manaventures.vc · Not right? Tell us
How we know: Outliers Fund's portfolio page · Not right? Tell us
How we know: Perridon Ventures's portfolio page · Not right? Tell us
How we know: Prime Movers Lab's portfolio page · a partner's Signal profile · board seat on SEC Form D · the VCSheet dataset · research · paradromics.com · Not right? Tell us
How we know: Red Beard Ventures's portfolio page · the VCSheet dataset · Not right? Tell us
How we know: Social Starts's portfolio page · the VCSheet dataset · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Wormhole Capital's portfolio page · Not right? Tell us
Also in the syndicate · 3
Reported raises · per SEC filings
Form D private placements$96.9M disclosed across 7 of 9 rounds · 2015–2023
▶$50.1MraisedNov 2023 · 53 investors · Other Health CareRule 506(b)
- Helmy EltoukhyExecutive Officer, Director
- Matthew AngleExecutive Officer, Director
- Zia HuqueDirector
- Amy KruseDirector
- Offering amount
- $51M
- Amount sold
- $50.1M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$8.9MraisedSep 2022 · 9 investors · Other Health CareRule 506(b)
- James BurrowsExecutive Officer, Director
- Amy KruseDirector
- Matthew AngleExecutive Officer, Director
- Adam KablanianDirector
- Offering amount
- $8.9M
- Amount sold
- $8.9M
- First sale
- Feb 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$28.2MraisedOct 2021 · 42 investors · Other Health CareRule 506(b)
- Matthew AngleExecutive Officer, Director
- James BurrowsExecutive Officer, Director
- Adam KablanianDirector
- Amy KruseDirector
- Offering amount
- $28.2M
- Amount sold
- $28.2M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.4MraisedApr 2019 · 6 investors · Other Health CareRule 506(b)
- Matt AngleExecutive Officer, Director
- Enke BashllariDirector
- Adam KablanianDirector
- Yifan KongDirector
- Edmund HuberDirector
- Offering amount
- $3M
- Amount sold
- $1.4M
- First sale
- Mar 2019
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$7.1MraisedMay 2018 · 34 investors · Other Health CareRule 506(b)
- Thomas KrummelDirector
- Matthew R AngleExecutive Officer, Director
- Ron KellyDirector
- Enke BashllariDirector
- Adam KablanianDirector
- Offering amount
- $7.1M
- Amount sold
- $7.1M
- First sale
- Feb 2018
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$175KraisedJun 2017 · 2 investors · Other Health CareRule 506(b)
- Matt AngleExecutive Officer, Director
- Ron KellyDirector
- Thomas KrummelDirector
- Adam KablanianDirector
- Offering amount
- $1M
- Amount sold
- $175K
- Minimum investment
- $25K
- Proceeds to insiders
- $50K
- First sale
- May 2017
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
▶$985KraisedMar 2016 · 16 investors · Other TechnologyRule 506(b)
- Matt AngleExecutive Officer, Director
- Edmund HuberExecutive Officer, Director
- Adam KablanianDirector
- Offering amount
- $1.2M
- Amount sold
- $985K
- Minimum investment
- $10K
- Proceeds to insiders
- $160K
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware, 2015
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Company profile
researched Aug 2026Paradromics is a neurotechnology company developing a high-data-rate platform for exchanging information between the brain and computers. Its lead product, the Connexus BCI, is an implantable brain-computer interface engineered to restore communication for people who have lost the ability to speak. The company positions the device as a platform technology, with successive generations intended to broaden the range of applications from brain-based therapeutics toward wider human-computer integration.
The company describes years of engineering work, safety testing and preclinical research preceding the Connexus BCI's first-in-human study, which follows FDA approval for clinical studies in humans. Paradromics also works with academic medical institutions on translational BCI research, aligning academic innovation with its own device platform. Founder and CEO Matt Angle frames brain interfaces as a complement to artificial intelligence, connecting computational algorithms with neural data.
Business model
Paradromics is developing a proprietary implantable medical device platform (Connexus BCI) intended for clinical use, advancing it through regulatory approval and human clinical studies, and collaborating with academic medical institutions on translational research.
Traction
The Connexus BCI received FDA approval for clinical studies in humans, and press coverage in mid-2026 reported the first clinical implantation of the company's first-generation brain-computer interface in a patient with impaired speech.
Latest developments
In June 2026, coverage reported the first-in-human wireless brain implant performed by physicians in Michigan. In July 2026, the company announced the appointment of William J. Marks, Jr., MD, MS-HCM as Chief Clinical Officer. Shares in the company are listed as available to accredited investors on the EquityZen secondary marketplace.
▸Full profile — market position, technology, go-to-market, geography
Market position
Paradromics presents Connexus as the fastest brain-computer interface in the world and itself as bringing to market the first high-data-rate interface between brains and computers.
Emphasis on data rate and bandwidth of the neural interface, with the Connexus device described as the fastest BCI in the world and as a platform intended to scale across successive device generations.
Technology
A high-data-rate, wireless implantable brain-computer interface, marketed as the Connexus BCI, designed to record neural signals at high bandwidth and decode them for communication, including speech decoding and control of digital devices.
Go-to-market
People who have lost the ability to speak or to control digital devices due to neurological impairment, reached through clinical study sites and academic medical institutions.
Geography
Headquartered in Austin, Texas, United States; a first-in-human implant was reported at a clinical site in Michigan.
Compiled by commissioned research from 8 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Founder mafia
3 people who came through Paradromics went on to found or lead other companies.
Non-dilutive funding · 2 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2021 | $3.2M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2016 | $797.8K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Timeline · 16
launches, deals, and filingsParadromics announced FDA approval to embed BCI software in personal devices, expanding BCI access to personal computing devices within the Connect-One clinical study.
Press announcements reported the appointment of William J. Marks, Jr., MD, MS-HCM as Chief Clinical Officer of Paradromics.
Press coverage reported that physicians in Michigan placed a first-in-human wireless brain implant in a woman with impaired speech, described as the first clinical implantation of the company's first-generation brain-computer interface.
Paradromics states its Connexus BCI was recently approved by the FDA for clinical studies in humans, enabling a first-in-human study following preclinical research and safety testing.
Paradromics received FDA IDE approval to conduct first-in-human clinical trials; press coverage described regulatory approval to test the BCI in a small trial assessing safety and efficacy for speech restoration.
Reported launch of a patient registry in advance of the company's human clinical trial.
Paradromics was accepted into the FDA's Total Product Life Cycle Advisory Program (TAP) Pilot for innovative devices.
The Connexus BCI received a second Breakthrough Device Designation covering use by individuals with severe motor deficits to control computer devices.
Series A of $33 million intended to help launch the first-in-human clinical trial of the Connexus BCI.
$33M source ↗
The U.S. FDA granted the Connexus Brain-Computer Interface (also described as the Connexus Direct Data Interface) Breakthrough Device Designation, providing expedited review for transformative devices treating irreversibly debilitating conditions.
Seed round of $20 million led by Prime Movers Lab, following $10M in earlier private funding and $15M of public funding from NIH and DARPA.
$20M source ↗
As part of the Prime Movers Lab investment, Partner Dr. Amy Kruse joined the Paradromics board of directors.
Paradromics was awarded a $3.2 million Phase II SBIR grant from the NIH to develop high-density intracortical microelectrode arrays for clinical applications, including collaboration with Massachusetts General Hospital's Center for Neurotechnology and Neurorecovery.
$3.2M source ↗
In late 2019 Paradromics moved from developing core technology capabilities to building a marketable medical device, the Connexus Brain-Computer Interface.
After securing an NIH SBIR and a DARPA contract collectively worth about $15 million within its first two years, Paradromics raised venture funds in 2018.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 8
primary sources listed
- Paradromics Turning Data Into Medicineparadromics.com · web
- Paradromics Raises $33 Million in Funding, Achieves Breakthrough Medical Device Designation from FDAparadromics.com · web
8 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Paradromics do?
- Paradromics develops the Connexus high-data-rate implantable brain-computer interface to restore communication for people unable to speak.
- Who founded Paradromics?
- Paradromics was founded by Matt Angle in 2015.
- Who are Paradromics's investors?
- Paradromics's investors include 15th Rock, Alpha Edison, Anthropy Partners, ATEL Ventures, Capital Factory, CloudStone Capital, CoastCap, Deepwater Asset Management and 26 more.
- How much funding has Paradromics raised?
- Paradromics has disclosed $96.9M raised across 7 of its 9 known rounds.
- Where is Paradromics headquartered?
- Paradromics is headquartered in Austin, US.